DGM
NTLA icon

Darwin Global Management’s Intellia Therapeutics NTLA Stock Holding History

Darwin Global Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-605,587
Closed -$71.6M – 8
2021
Q4 		$71.6M Sell
605,587
-146,437
-19% -$18.3M 10.94% 2
2021
Q3 		$101M Sell
752,024
-1,107,902
-60% -$168M 18.57% 2
2021
Q2 		$301M Buy
+1,859,926
New +$145M 48.58% 1

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Darwin Global Management's NTLA Position: Q1 2022 in Review

Darwin Global Management sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 605,587 shares — an estimated $71.6M sold.

Darwin Global Management first reported a position in NTLA in Q2 2021 and held it in 3 quarters. The position peaked at $301M in Q2 2021. 349 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • Darwin Global Management reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Darwin Global Management sold 605,587 Intellia Therapeutics shares in Q1 2022, an estimated $71.6M.
  • Darwin Global Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 3 quarters.
  • Darwin Global Management's Intellia Therapeutics position peaked at $301M in Q2 2021.
  • 349 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Darwin Global Management's 13F filing for Q1 2022, filed 16 May 2022.